2. Academic Validation
  3. Preliminary in vitro and in vivo investigation of a potent platelet derived growth factor receptor (PDGFR) family kinase inhibitor

Preliminary in vitro and in vivo investigation of a potent platelet derived growth factor receptor (PDGFR) family kinase inhibitor

  • Bioorg Med Chem Lett. 2018 Jun 1;28(10):1781-1784. doi: 10.1016/j.bmcl.2018.04.030.
Elizabeth A Wilson 1,  Wade A Russu 2,  Hassan M Shallal 1
Affiliations

Affiliations

  • 1 Department of Pharmaceutics and Medicinal Chemistry, Thomas J. Long School of Pharmacy and Health Sciences, Stockton, CA 95211, USA.
  • 2 Department of Pharmaceutics and Medicinal Chemistry, Thomas J. Long School of Pharmacy and Health Sciences, Stockton, CA 95211, USA. Electronic address: wrussu@pacific.edu.
PMID: 29678462 DOI: 10.1016/j.bmcl.2018.04.030
Abstract

Aberrant expression of wild-type and mutant forms of the platelet-derived growth factor receptor (PDGFR) family of Receptor Tyrosine Kinases has been implicated in various oncologic indications such as leukemias, gliomas, and soft tissue sarcomas. Clinically used kinase inhibitors imatinib and sunitinib are potent inhibitors of wild-type PDGFR family members, but show reduced binding to mutant forms. Here we describe compound 5 which binds to both wild-type and oncogenic mutant forms of PDGFR family members, and demonstrates both cellular and in vivo activity.

Keywords

Cancer; KIT; Kinase inhibitor; PDGFR; Systemic mastocytosis.

Figures